Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organogenesis Holdings reports Q4 revenue decline but exceeds guidance

Organogenesis Holdings faced revenue decline in Q4 2022 but exceeded guidance expectations.
Operational progress in clinical trials and a healthy cash position are notable strengths.
Challenges include declining product sales and increased operating expenses.
Strategic investments and growth opportunities in clinical initiatives are key focus areas for 2023.

Organogenesis Holdings reports robust Q1 revenue growth and strategic focus

Organogenesis Holdings delivered strong revenue growth driven by Advanced Wound Care products, while facing challenges with increased expenses and a net loss.
The company's focus on innovation, market expansion, and cost management presents opportunities for sustained growth and competitive positioning.
Navigating regulatory requirements and market dynamics will be crucial for Organogenesis to capitalize on opportunities and mitigate challenges in the upcoming quarters.

Organogenesis Holdings faces revenue challenges amidst strong business trends

Organogenesis Holdings faced revenue challenges due to LCDs impacting products, leading to withdrawn guidance. Despite this, the company maintained a strong gross profit margin and focused on strategic sales shifts. Opportunities for growth exist in product focus and ongoing trials.

Organogenesis reports Q3 revenue decline, eyes growth amid regulatory shifts

Organogenesis Holdings navigated challenges in Q3 2023 with a focus on operational efficiency, financial strength, and strategic growth initiatives for the future.
While facing revenue declines and market uncertainties, the company capitalized on positive regulatory developments and operational advancements to drive performance.
Looking ahead, Organogenesis aims to address challenges, seize growth opportunities, and maintain its competitive edge in the evolving healthcare market landscape.

Organogenesis Holdings reports Q4 revenue decline but anticipates 2024 growth

Organogenesis Holdings faced challenges in Q4 but showed positive momentum and progress in clinical trials. The company expects revenue growth in 2024 and is focusing on customer engagement and new product launches for further expansion.

Organogenesis Holdings beats revenue expectations, eyes FDA approval for ReNu

Organogenesis Holdings demonstrated solid financial performance in Q1, with revenue exceeding expectations and improved operating metrics.
While facing challenges in certain revenue segments, the company's focus on innovation and regulatory progress presents growth opportunities.
Maintaining a strong cash position and reaffirming revenue guidance underscore Organogenesis' resilience and strategic outlook for the future.

Organogenesis Holdings exceeds Q3 revenue guidance, focuses on innovation

Organogenesis Holdings delivered a strong performance in Q3 2024, surpassing revenue guidance and demonstrating solid financial results.
While facing challenges such as potential market disruption and regulatory issues, the company remains focused on strategic initiatives and innovation to drive growth.
With opportunities in Medicare reimbursement, product development, and regulatory milestones, Organogenesis is well-positioned for future success and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Boston, Massachusetts--(Newsfile Corp. - October 14, 2021) -  Block & Leviton is investigating Organogenesis Holdings, Inc. (NASDAQ: ORGO) for potential securities law violations. Investors who have lost money in their Organogenesis Holdings, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/orgo.What is this all about?On October 12, 2021, Value Investors Club issued a report alleging issues at Organogenesis Holdings, Inc., indicating that the...

ORGANOGENSIS INVESTIGATION: Block & Leviton Is Investigating Organogenesis Holdings, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Organogenesis Holdings Inc. (NASDAQ: ORGO) resulting from allegations that Organogenesis may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Organogenesis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a continge

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Organogenesis Holdings Inc. Investors with Losses to Inquire About Class Action Investigation – ORGO

Atlanta, Georgia--(Newsfile Corp. - October 12, 2021) - Holzer & Holzer, LLC is investigating whether Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO) complied with federal securities laws. On October 12, 2021, Seeking Alpha published a report titled "Organogenesis falls on short report from Value Investors Club" which repeated claims made by a short seller, Value Investor Club, that Organogenesis had previously engaged in improper billing practices in connection with Medicare reimbursements.If you...

SHAREHOLDER ALERT: Investigation of Organogenesis Holdings Inc. Announced by Holzer & Holzer, LLC

CANTON, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2021 financial results will be reported after the market closes on Tuesday, November 9th.

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

DexCom

Progyny

Their products are better than those of their rivals, and their leads are increasing.

3 Innovative Growth Stocks That'll Make You Richer Through 2025

Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Organogenesis (ORGO) Run Higher on Rising Earnings Estimates?

PITTSBURGH, Aug. 23, 2021 /PRNewswire/ -- Net Health, a leading provider of cloud-based software for specialty medical providers, announced today that Organogenesis Holdings Inc. (Nasdaq: ORGO), has become the first company to utilize Net Health® Wound Care's latest CTP Connections Module to electronically submit insurance benefits verification forms. Through this partnership, hospital and outpatient wound care providers can quickly and efficiently verify benefits for Organogenesis's portfolio of cell and tissue-based products.

Net Health Partners with Organogenesis for More Efficient Insurance Benefits Verification

Organogenesis Holdings Inc (NASDAQ: ORGO) Q2 revenues increased 79% Y/Y to $123.2 million, edging out analysts' average expectation of $107.30 million. The increase was driven by a $51.7 million increase, or 87%, in net revenue of Advanced Wound Care products and a $2.5 million growth, or 27%, in net revenue of Surgical & Sports Medicine products.

Organogenesis Q2 Earnings Beat Expectations; Sales Jump 79%; Raises FY21 Sales Outlook

The stock price of Organogenesis Holdings Inc (NASDAQ: ORGO) increased by over 15% pre-market. This is why it happened.

ORGO Stock Price Increases Over 15% Pre-Market: Why It Happened

Organogenesis Holdings' (ORGO) CEO Gary Gillheeney on Q2 2021 Results - Earnings Call Transcript

Organogenesis (ORGO) delivered earnings and revenue surprises of 114.29% and 16.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Q2 Earnings and Revenues Beat Estimates

Shares of Organogenesis Holdings (NASDAQ:ORGO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 400.00% year over year to $0.15, which beat the estimate of $0.07.

Organogenesis Holdings: Q2 Earnings Insights

CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and six months ended June 30, 2021.

Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results

CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced a new credit agreement with Silicon Valley Bank, the lead agent, and several other lenders. The agreement provides for a credit facility in the aggregate principal amount of $200 million, consisting of a $75 million term loan facility and a $125 million revolving credit facility. The proceeds from the term loan and revolving credit facility will be used for general corporate purposes and the repayment of the Company's existing $100 million credit facility with Silicon Valley Bank.

Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank

Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organogenesis (ORGO) Reports Next Week: Wall Street Expects Earnings Growth

CANTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, August 9th.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021

Acer Therapeutics

Cumberland Pharma

Xencor

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Organogenesis (ORGO) Stock Jumps 7.7%: Will It Continue to Soar?

The company will be a component of a high-profile stock index.

Why Organogenesis Holdings Blasted 7.7% Higher Today

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript

Organogenesis (ORGO) delivered earnings and revenue surprises of 275.00% and 18.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from the sale of non-PuraPly products was $61.2 million, not $32.0 million. The corrected release follows:

CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

Shares of Organogenesis Holdings (NASDAQ:ORGO) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 143.75% year over year to $0.07, which beat the estimate of ($0.02).

Organogenesis Holdings: Q1 Earnings Insights

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three months ended March 31, 2021.

Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company's Board of Directors, effective May 7, 2021. The Company also announced that Wayne Mackie resigned as a member of the Company's Board of Directors effective May 7, 2021. Mr. Mackie's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.

News for Organogenesis Holdings Stock (ORGO)